Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APX-115 in Contrast Induced Acute Kidney Injury
NCT05758896Phase 2Completed
- Sponsor
- AptaBio Therapeutics Inc.
- Start
- Dec 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in contrast-induced acute kidney injury (CI-AKI) comparing Isuzinaxib (APX-115) with Placebo (2 arms). Primary endpoints: Adverse Events, Vital Signs and 3 more. Started Dec 2023; status: completed.
02
Drugs
isuzinaxib
03
Conditions
contrast-induced acute kidney injury (CI-AKI)
Beyond the preview
Go deeper on NCT05758896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05758896.